Oral Presentation
ESA-SRB-NZSE-CaSR 2026 in conjunction with ENSA
Days
Saturday, 31st October
Sunday, 1st November
Monday, 2nd November
Tuesday, 3rd November
Wednesday, 4th November
Search
Speakers
Outcome of Phase-2 trial of Canvuparatide for Hypoparathyroidism
(#232)
Michael Mannstadt
1
Massachusetts General Hospital and Havard Medical School, Boston, MA, United States
TBC**